Last reviewed · How we verify

cDMARD — Competitive Intelligence Brief

cDMARD (cDMARD) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cDMARD. Area: Immunology.

phase 3 cDMARD peptidyl arginine deiminase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

cDMARD (cDMARD) — Eli Lilly and Company. cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
cDMARD TARGET cDMARD Eli Lilly and Company phase 3 cDMARD peptidyl arginine deiminase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cDMARD class)

  1. Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cDMARD — Competitive Intelligence Brief. https://druglandscape.com/ci/cdmard. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: